SCHEMBL162284

SCHEMBL162284

O=C(O)c1cccc2c(O)nc(C(F)(F)c3ccc(F)cn3)nc12

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.36
▸ HPGD P15428 1/20 0.36
▸ KDM4A O75164 1/20 0.34
▸ RAB9A P51151 1/20 0.34
▸ EGLN1 Q9GZT9 1/20 0.34
▸ HIF1AN Q9NWT6 1/20 0.34
▸ L3MBTL1 Q9Y468 1/20 0.34
▸ DHODH Q02127 1/20 0.34
▸ ALDH1A1 P00352 2/20 0.33
▸ NR4A1 P22736 1/20 0.33
▸ NR4A2 P43354 1/20 0.33
▸ NR4A3 Q92570 1/20 0.33
▸ CSNK2A2 P19784 1/20 0.33
▸ CSNK2B P67870 1/20 0.33
▸ P2RX7 Q99572 2/20 0.33
▸ PIM1 P11309 1/20 0.33
▸ PIM2 Q9P1W9 1/20 0.33
▸ ALB P02768 1/20 0.33
▸ RPS6KB1 P23443 1/20 0.32
▸ AKT1 P31749 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL163623 0.83 NR1H2 (0.35) KDM4EL3MBTL1ALDH1A1LMNA
SCHEMBL162604 0.83 JAK2 (0.34) —
SCHEMBL161396 0.82 PDE10A (0.36) KDM4ERAB9AL3MBTL1ALDH1A1PIM1
SCHEMBL160537 0.81 ADORA2A (0.33) —
SCHEMBL158172 0.81 ADORA2A (0.41) KDM4EHPGDALDH1A1
SCHEMBL161073 0.80 P2RX3 (0.33) —
SCHEMBL160702 0.77 JAK2 (0.44) —
SCHEMBL161917 0.75 RPS6KB1 (0.41) PIM1PIM2RPS6KB1AKT1
SCHEMBL161934 0.75 MAPT (0.38) KDM4EALDH1A1PIM1PIM2RPS6KB1
SCHEMBL161445 0.73 KDM4E (0.33) KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8633207-B2 Quinazoline compounds and methods of use thereof AMBIT BIOSCIENCES CORPORATION (US) 2014-01-21 — — US disclosed
EP-2611789-A1 QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF Ambit Biosciences Corporation (US) 2013-07-10 — — EP disclosed
WO-2012030948-A1 QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF AMBIT BIOSCIENCES CORPORATION (US) 2012-03-08 — — WO disclosed
US-20120053174-A1 QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF AMBIT BIOSCIENCES CORPORATION 2012-03-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053174-A1 QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF JAK3, JAK2, TYK2 KDM4E 1840/4885HPGD 2294/4885KDM4A 1521/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback